Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iothalamate is an iodinated radiopaque contrast medium and diagnostic agent used primarily for medical imaging and the assessment of renal function. As a marker for glomerular filtration rate (GFR), it is considered a reference standard because it is filtered by the glomeruli without significant tubular secretion or reabsorption. It is available in non-radioactive formulations (e.g., Conray) for various diagnostic procedures, including excretory urography, angiography, and CT scan enhancement of the brain and abdominal organs. Additionally, radioisotopic versions such as iothalamate sodium I-125 (Glofil-125) are utilized for precise GFR measurement, while Iotrex (sodium iothalamate I-125) was developed as a liquid radiation source for the GliaSite radiation therapy system to treat brain cancer via internal brachytherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iothalamate.